Glaxosmithkline

This study tests a new combined vaccine (MMRVNS) against measles, mumps, rubella, and chickenpox in healthy children aged 15 months to 6 years. About 1,200 children who already received a first dose of a similar vaccine will get a second dose of either the new vaccine or the lice…

This early-stage study tests a new pneumococcal vaccine booster in 45 healthy toddlers aged 12 to 15 months. The goal is to check for side effects like tenderness, fever, or sleepiness after a single dose. The vaccine aims to protect against bacterial pneumonia, and results will …

This study tests a new drug, belantamab mafodotin, added to standard chemotherapy for adults newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. About 60 participants will receive different doses to find the best balance of safety and e…

This study tests a drug called momelotinib in 192 adults with VEXAS syndrome, a rare and serious inflammatory condition caused by a genetic mutation. The goal is to see if the drug can reduce disease activity, with participants receiving either momelotinib or a placebo. The trial…

This study tests a new oral drug, GSK3772701, for adults with uncomplicated malaria caused by the P. falciparum parasite. About 70 participants will receive different doses and treatment durations to check safety and how the drug works in the body. The goal is to find a well-tole…

This early-stage study tests a new pneumococcal vaccine (Pn-MAPS30plus) in 60 healthy infants to see if it is safe and what side effects it causes. Babies will receive three doses starting around 2 months old, followed by a booster at 12-15 months. The study compares the new vacc…

This phase 3 study tests a new drug, GSK5733584, against standard chemotherapy in about 450 adults with ovarian cancer that has stopped responding to platinum-based treatments. The goal is to see if the new drug can delay cancer growth and improve survival. Researchers will also …

This study tests a drug called depemokimab in people with Type 2 asthma who are at risk of serious attacks. The goal is to see if adding this drug to standard care can reduce asthma attacks, help patients achieve remission (no attacks and no need for steroid pills), and slow lung…

This study compares a new drug, velzatinib, to the current standard treatment imatinib in people with advanced GIST that has spread or cannot be removed by surgery. About 800 adults who have not had prior treatment for advanced GIST will be randomly assigned to receive either vel…

This phase 3 study tests a new drug, GSK5733584, against standard chemotherapy for people whose endometrial cancer has come back or persists. About 600 adults with recurrent endometrial cancer will be randomly assigned to receive either the new drug or chemotherapy. The goal is t…

This study tests a new medicine, GSK3862995B, for adults with bronchiectasis, a long-term lung condition that causes coughing and frequent infections. About 400 people will be randomly assigned to receive one of two doses of the drug or a placebo. The main goal is to see if the d…

This study tests a new drug called camlipixant in 420 adults with moderate-to-severe irritable bowel syndrome (IBS) that causes diarrhea or mixed bowel habits. Participants will receive either the drug or a placebo for 26 weeks to see if it reduces abdominal pain and improves sto…

This early-stage study will give a single dose of the experimental antibiotic gepotidacin to 20 hospitalized children aged 2 to 12 who are already receiving standard antibiotics for a bacterial infection or as a preventive measure. The main goal is to measure how the drug moves t…

This study follows African children who received a Shigella vaccine in earlier studies to see how long their immune protection lasts. No new vaccines are given—only blood samples are taken at 1, 2, and 3 years after the last shot. The goal is to understand the vaccine's long-term…